Who is CureOne? A group of internationally renowned experts in the field of health care who understand the complex interplay of precision medicine and associated policies and their role to provide quality care at lower cost.

At CureOne, we’re focused on high-quality, standardized data collection with the sole purpose to aid in the cure of persistent diseases. Open access will be given to all interested parties allowing any organization to easily obtain richly detailed laboratory data including genetic-level testing and associated clinical outcomes.

Leadership Board of Directors N1 Registry Clinical Leadership Lab Oversight Committee

Leadership

Dane J. Dickson, M.D. | CEO & Founder, CureOne
Director of Precision Medicine Policy and Registries, Knight Cancer Center at Oregon Health and Science University

Dr. Dickson graduated in 1992 from the University of Utah with a BA in chemistry and a minor in Mandarin Chinese. He attended medical school at the University of Utah graduating in 1996 with honors. Subsequently he completed an internal medicine residency at Washington University in St. Louis in 1999. He specialized at the Huntsman Cancer Institute at the University of Utah.

read more

In 2001 he started a solo practice (Teton Oncology) in Rexburg, Idaho, which eventually encompassed the geography of over 8,000 square miles of Idaho and Wyoming. In 2010 his small group practice was acquired by a local hospital and Dr. Dickson spearheaded the development of the Teton Cancer Institute and served as its Medical Director until 2014.

Also in 2001 he started the Summarius Corporation, a medical informatics company specializing in clinical trial review and development of OIG compliant graphical materials for education and training. This format was adopted by two large pharmaceutical companies.

In 2012 he started working with Noridian LLC a Medicare Administrative Contractor as an oncology subject matter expert and then in 2013 he accepted the position of Director of Clinical Science for the Molecular Diagnostic Program (MolDX) with Palmetto GBA (another CMS MAC contractor). In this capacity he advised Medicare on policy for implementation of molecular testing to personalize medicine. He left that position in early 2014 to work on broader methods of advancing personalized medicine.

In 2014 he spearheaded the development of a national endeavor to advance molecular medicine through establishing partnerships and repurposing of existing infrastructures. The resulting Cure-One (formerly Molecular Evidence Development Consortium [MED-C]) has brought payers, providers, patients, pharma, laboratory and regulators together to allow the stepwise introduction of personalized medicine. He is currently serving as the CEO of this group.

In 2015 Dr. Dickson accepted an adjunct position at Oregon Health & Sciences University. He is their Director of Precision Medicine Policy and Registries.
Dr. Dickson has been an active member of the American Society of Clinical Oncology (ASCO). He served on ASCO’s Clinical Practice Committee from 2002-2005. In 2011 he helped revive the Idaho Society of Clinical Oncology (ISCO) and served as President from 2012-2014. He was elected to the executive sub-committee of the ASCO State Affiliate Council in 2013 and in 2014.

On a personal note, Dr. Dickson is the second oldest in a family of eight boys. He is happily married and has three sons ranging from 16 to 21. He enjoys backpacking/hiking (especially in the Wind River Range of Wyoming), running, biking, and snow skiing. He is active in his community serving as an advisor to the President of Brigham Young University Idaho as well as being a faithful member of the Church of Jesus Christ of Latter-day Saints.

read less

Rebecca Owens
Chief Commercial Officer

Rebecca brings 18 years of experience in developing solutions for delivering high quality cancer diagnostic testing and data solutions in pathology and oncology. Her primary focus has been identifying technology platforms that easily access diagnostic information in a collaborative delivery model between healthcare providers, enabling the confidence to deliver the best therapies for patients. Rebecca is committed to finding novel ways to bringing patient data together to generate new understandings that will ultimately advance patient care in the clinic.

read more

As a leader, Rebecca has proven success in business development, strategic sales & marketing, and corporate planning. She has worked with and consulted for top technology companies, diagnostic laboratories and startup ventures. Before joining CureOne, Rebecca served as the Sr. Director of Clinical Collaborations at Foundation Medicine whereby she was integral in data sharing initiatives such as the Precision Medicine Exchange Consortium (PMEC)™, data transfer to clinics and developed a novel reporting solution for pathology partners called GeneKit™

read less

Alex Fichtenholtz, Ph.D.
Sr. Vice President of Cancer Genomics and Data Science

Dr. Alex Fichtenholtz is a computational biologist with deep experience in next-generation sequencing, algorithm development, systems biology, and artificial intelligence. Prior to joining Cure-One, he worked at Foundation Medicine where he created industry leading genetic variant detection algorithms, core modules the F1 and F1 Heme comprehensive genomic profiling platforms, that have been used to process hundreds of thousands of clinical grade solid and liquid tumor specimens. Dr. Fichtenholtz has authored manuscripts in the areas of tumor genomic sub-typing, molecular diagnostic development and validation, and cancer drug delivery.

read more

His research interests include clinical interpretation of NGS testing results and clonal evolution in cancer. At Cure-One he sets the strategy for managing tumor profiling data and develops technology for participating clinicians and researchers to better leverage our clinicogenomic database.

read less

Board of Directors

Jeff Allen Ph.D. | Chairman of the Board
CEO, Friends of Cancer Research

Jeff Allen is President and CEO of Friends of Cancer Research (Friends). Friends is an advocacy organization based in Washington, DC that drives collaboration among partners from every healthcare sector to power advances in science, policy, and regulation that speed life-saving treatments to patients. During the past 20 years, Friends has been instrumental in the creation and implementation of policies ensuring patients receive the best treatments in the fastest and safest way possible.

read more

For over 10 years, Jeff has been a driving force in the growth and success of the organization. Under his leadership, Friends has evolved into a nimble, forward-thinking policy, public affairs, and research organization. As President and CEO, he leads the strategic development and implementation of Friends’ scientific, policy, research, and legislative initiatives, as well as overseeing Board governance and organizational operations.

As a thought leader on many issues related to the Food and Drug Administration, regulatory strategy, and healthcare policy, he is regularly published in prestigious medical journals and policy publications. In addition to participating in major scientific and policy symposiums around the country each year, Jeff has had the honor to be called to testify before Congress on multiple occasions and regularly contributes his expertise to the legislative process. Recent Friends initiatives include the establishment of the Breakthrough Therapies designation and the development of the Lung Cancer Master Protocol (Lung-MAP), a unique partnership that will accelerate and optimize clinical trial conduct for new drugs.

Jeff has the privilege to also serve on a variety of influential committees, boards, and advisory councils including the Alliance for a Stronger FDA (Board Member, Past President), Cure-One (Board Chair), Lung-MAP Senior Leadership Team Member, and a participant on working groups convened by the National Academies of Medicine and President’s Council of Advisors on Science and Technology (PCAST).

Prior to joining Friends, Jeff was an endocrinology researcher at the National Institutes of Health. His background in cancer research focused upon molecular changes associated with cancer formation as well as treatments to prevent cancer progression. Jeff received his Ph.D. in cell and molecular biology from Georgetown University, and holds a Bachelor’s of Science in Biology from Bowling Green State University.

read less

Ron Collette, C.I.S.S.P.
Board Member

Before retiring at the end of 2015, Ronald Collette was previously Chief Information Officer for Foundation Medicine, with nearly 30 years of professional experience in information technologies, including work for various Fortune-500 organizations such as Fluor Corporation, Pacific Life, Countrywide Mortgage, and the Resolution Trust Corporation. Before joining Foundation Medicine, he was the Chief Information Officer for Clarient, a GE Healthcare Company. Prior to joining Clarient, he was a founding partner of the highly regarded Traxx Consulting Inc.; a boutique consultancy focused on information security, team development, and technical architecture.

read more

Mr. Collette regularly spoke at a number of security and IT related events such as International Standards Organization (ISO) conference, SecureWorld Expo and InfoSeCon. He was also a regular columnist and research analyst for Computer Economics. Mr. Collette co-authored two books on information security “The CISO Handbook: A Practical Guide to Securing Your Company” and the companion publication “CISO Soft Skills: Securing Organizations Impaired by Employee Politics, Apathy and Intolerant Perspectives.” Both of these books are utilized as course material for numerous advanced education and university masters programs on security leadership. His contribution to the information technology industry is represented by numerous publications, papers and presentations.

Mr. Collette holds a BS in economics with minors in accounting and business administration; with post graduate work in software engineering.

read less

Brian Druker, M.D.
Director, Knight Cancer Institute at Oregon Health & Science University; JELD-WEN Chair of Leukemia Research; Investigator, Howard Hughes Medical Institute

Brian Druker, M.D., revolutionized the treatment of cancer through research that resulted in the first drug to target the molecular defect of a cancer while leaving healthy cells unharmed. Marketed under the name Gleevec®, his discovery turned a once-fatal cancer, Chronic Myeloid Leukemia, into a manageable condition. Treatment with Gleevec received FDA approval in record time, was featured on the cover of Time magazine, and established Dr. Druker as a pioneer in the field of precision medicine. Most important, his discovery became a new proof of principal for targeted therapies, spurring the development of more than 50 similar precision therapies for other cancers.

read more

Now, Dr. Druker is applying key principles of precision medicine to early detection. Earlier detection of lethal cancers represents the greatest opportunity to increase cancer survival rates. Thanks to $1 billion in philanthropic funding, Dr. Druker is developing a large-scale early detection program that builds upon the scientific strengths of OHSU’s Knight Cancer Institute.

Druker has been recognized with numerous awards, including the Warren Alpert Prize from Harvard Medical School, the Lasker-DeBakey Award for Clinical Medical Research, and the Japan Prize in Healthcare and Medical Technology. He has been elected to the National Academy of Medicine, the National Academy of Sciences and the American Academy of Arts and Sciences.

read less

Mark B. McClellan M.D., Ph.D.
Director and Robert J. Margolis, M.D., Professor of Business, Medicine and Health Policy, Duke University.

Mark B. McClellan, M.D., Ph.D., is a doctor and an economist whose work has addressed a wide range of strategies and policy reforms to improve health care, including payment reforms to promote better outcomes and lower costs, methods for development and use of real-world evidence, and approaches for more effective drug and device innovation. Dr. McClellan is a former administrator of the Centers for Medicare & Medicaid Services (CMS) and former commissioner of the U.S. Food and Drug Administration (FDA), where he developed and implemented major reforms in health policy.

read more

Dr. McClellan has served as a member of the President’s Council of Economic Advisors and as Deputy Assistant Secretary of the Treasury for Economic Policy. He was also a Senior Fellow at the Brookings Institution and a professor of economics and medicine at Stanford University where he directed the Program on Health Outcomes Research.

read less

Marc Samuels, J.D.
Founder and CEO of ADVI

Marc Samuels is the Founder and CEO of ADVI (formerly HillCo Health). Samuels is responsible for ADVI’s strategic vision, leadership and operational execution, as well as development and execution strategies designed to grow business outside of North America. He provides senior relationship management for the firm’s top clients across life sciences, digital health, managed care and services. Samuels is also an author and speaker, including In Vivo, Journal of Oncology Practice, Medical Economics and Texas Medicine. He is a graduate of The University of Texas School of Law, Yale School of Medicine and the University of Michigan.

Sean Tunis M.D., M.Sc.
CEO | Founder, Center for Medical Technology Policy

Sean Tunis, MD, MSc is the Founder, President, and Chief Executive Officer of the Center for Medical Technology Policy in Baltimore, Maryland. CMTP’s main objective is to improve the quality and relevance of clinical research by providing a neutral forum for collaboration among experts, stakeholders and decision makers. Dr. Tunis was a member of the Institute of Medicine Committee on Initial National Priorities for Comparative Effectiveness Research. He advises a wide range of domestic and international public and private health care organizations on issues of comparative effectiveness, evidence based medicine, clinical research, reimbursement and health technology policy.

read more

Through September of 2005, Dr. Tunis was the Director of the Office of Clinical Standards and Quality and Chief Medical Officer at the Centers for Medicare and Medicaid Services (CMS). In this role, he had lead responsibility for clinical policy and quality for the Medicare and Medicaid programs, which provide health coverage to over 100 million US citizens. Dr. Tunis supervised the development of national coverage policies, quality standards for Medicare and Medicaid providers; quality measurement and public reporting initiatives, and the Quality Improvement Organization program. As Chief Medical Officer, Dr. Tunis served as the senior advisor to the CMS Administrator on clinical and scientific policy. He also co-chaired the CMS Council on Technology and Innovation.

Dr. Tunis joined CMS in 2000 as the Director of the Coverage and Analysis Group. Before joining CMS, Dr. Tunis was a senior research scientist with the Technology Assessment Group, where his focus was on the design and implementation of prospective comparative effectiveness trials and clinical registries. Dr. Tunis also served as the Director of the Health Program at the Congressional Office of Technology Assessment and as a health policy advisor to the U.S. Senate Committee on Labor and Human Resources, where he participated in policy development regarding pharmaceutical and device regulation.

He received a B.S. degree in Biology and History of Science from the Cornell University School of Agriculture, and a medical degree and masters in Health Services Research from the Stanford University School of Medicine. Dr. Tunis did his residency training at UCLA and the University of Maryland in Emergency Medicine and Internal Medicine. He is board certified in Internal Medicine and holds adjunct faculty appointments at Johns Hopkins, Stanford and the University of California San Francisco Schools of Medicine.

read less

N1 Registry Clinical Leadership

Razelle Kurzrock, M.D. | Principal Investigator
Senior Deputy Center Director, Clinical Science; Director, Center for Personalized Cancer Therapy; Director, Clinical Trials Office; Team Leaders, Experimental Therapeutics; UCSD Moores Cancer Center; Chief, Division of Hematology and Oncology; UC San Diego School of Medicine

Dr. Razelle Kurzrock is known for developing the largest Phase 1 clinical trials department in the nation/world while at the University of Texas M.D. Anderson Cancer Center. A central theme of that program was the personalized medicine strategy, embodied in a protocol called PREDICT for Profile-related Evidence Determining Individualized Cancer Therapy. This approach utilized advanced molecular technologies to match patients with targeted cancer treatment that is more likely to work for their individual tumors.

read more

At Moores Cancer Center, Dr. Kurzrock’s charge is broad, including not just growing and innovating the center’s clinical trials program, but also heading its newly established Center for Personalized Cancer Therapy. This center focuses on precision medicine trials, using the most innovative genomically-targeted drugs and/or agents that arm the immune system. As a physician-scientist, Dr. Kurzrock brings extraordinary expertise and experience in clinical research, business operations, regulatory operations, financial and budget planning, and administrative oversight, in addition to her world-recognized work in translational science. Dr. Kurzrock is also Chief of the Division of Hematology and Oncology in the UC San Diego School of Medicine. Dr. Kurzrock received her MD degree from the University of Toronto and has over 650 peer-reviewed publications and a uniquely strong record of competitive grant funding within the setting of Phase I program building.

Dr. Kurzrock also has a strong history of building outstanding education/training programs. At University of Texas MD Anderson Cancer Center, she founded and directed the MS/PhD program (degree granting) in Human Biology and Patient-Based Research, as well as the Fellowship in Investigational Cancer Therapeutics. At UCSD Moores Cancer, she founded and directs the Fellowship in Personalized Cancer Therapy.

Dr. Kurzrock has four children and lives with her husband, Dr. Philip Cohen, a dermatologist, in San Diego, CA.

read less

Keith Flaherty, M.D.
Professor, Medicine, Harvard Medical School; Director of Henri and Belinda Termeer Center for Targeted Therapy, Cancer Center, Massachusetts General Hospital; Director of Clinical Research, Cancer Center, Massachusetts General Hospital; Editor-in-Chief of AACR’s Journal Clinical Cancer Research

Dr. Flaherty is director, since 2012, of the Henri and Belinda Termeer Center for Targeted Therapy and, since 2014, director of Clinical Research at the Massachusetts General Hospital, and Professor of Medicine at Harvard Medical School. As described in the nearly 200 peer reviewed primary research reports and review articles he has authored or co-authored, Dr. Flaherty and colleagues made several seminal observations recently that have defined the treatment of melanoma when they established the efficacy of BRAF, MEK and combined BRAF/MEK inhibition in patients with metastatic melanoma in a series of New England Journal of Medicine articles for which Dr. Flaherty was the first author.

read more

Dr. Flaherty also has been a leader in assessing and identifying mechanisms of de novo and acquired resistance to BRAF inhibitor therapy and clinically evaluating next generation inhibitors, work that has had implications for resistance to targeted therapy regimens used to treat other malignant diseases. Reflecting the importance of his clinical and translational work, Dr. Flaherty has received extensive NCI funding support with K12, K23, SPORE and two RO1 grants. He is the principal investigator of the NCI MATCH trial, the first NCI-sponsored trial assigning patients to targeted therapy independent of tumor type on the basis of DNA sequencing detection of oncogenes. He has made major commitments to ECOG as chair of the Developmental Therapeutics Committee and in 2013 was appointed as ECOG Deputy Chair for Biomarker Science.

read less

Brian Druker, M.D.
Director, Knight Cancer Institute at Oregon Health & Science University; JELD-WEN Chair of Leukemia Research; Investigator, Howard Hughes Medical Institute

Brian Druker, M.D., revolutionized the treatment of cancer through research that resulted in the first drug to target the molecular defect of a cancer while leaving healthy cells unharmed. Marketed under the name Gleevec®, his discovery turned a once-fatal cancer, Chronic Myeloid Leukemia, into a manageable condition. Treatment with Gleevec received FDA approval in record time, was featured on the cover of Time magazine, and established Dr. Druker as a pioneer in the field of precision medicine. Most important, his discovery became a new proof of principal for targeted therapies, spurring the development of more than 50 similar precision therapies for other cancers.

read more

Now, Dr. Druker is applying key principles of precision medicine to early detection. Earlier detection of lethal cancers represents the greatest opportunity to increase cancer survival rates. Thanks to $1 billion in philanthropic funding, Dr. Druker is developing a large-scale early detection program that builds upon the scientific strengths of OHSU’s Knight Cancer Institute.

Druker has been recognized with numerous awards, including the Warren Alpert Prize from Harvard Medical School, the Lasker-DeBakey Award for Clinical Medical Research, and the Japan Prize in Healthcare and Medical Technology. He has been elected to the National Academy of Medicine, the National Academy of Sciences and the American Academy of Arts and Sciences.

read less

Lab Oversight Committee

John Pfeifer M.D., Ph.D. | Committee Chair
Vice Chairman for Clinical Affairs, Department of Pathology & Immunology; Professor of Pathology & Immunology, Washington University School of Medicine

Dr. Pfeifer is board certified in Anatomic Pathology and subspecialty board certified in Molecular Genetic Pathology, and has been a practicing surgical pathologist for over 20 years. His academic interests are primarily focused on investigation of the role of molecular genetic testing in the analysis of tissue specimens, specifically on the methods and clinical settings in which molecular testing provides independent information that increases diagnostic accuracy, provides more accurate prognostic estimates, or can be used to guide therapy.

Christopher Corless, M.D., Ph.D.
Professor of Pathology Executive Director & Chief Medical Officer Knight Diagnostic Laboratories Oregon Health & Science University

After undergraduate studies at the Univ. of California, Berkeley, Dr. Corless received his MD and PhD degrees from Washington University, St. Louis. He did his residency training in Anatomic Pathology at the Brigham & Women’s Hospital, Boston, where he also completed fellowship training in GI Pathology and GU Pathology. He joined the faculty of Oregon Health & Science University in 1994 and was promoted to Professor in 2004. During his career he has served as the residency program director in Pathology and medical director of surgical pathology for OHSU Hospital. He is presently the Director and Chief Medical Officer of the Knight Diagnostic Laboratories at OHSU. An author on over 260 publications, Dr. Corless has expertise in the application of molecular diagnostics to the classification and prognostication of solid tumors.

Collin Pritchard M.D., Ph.D.
Associate Professor, Genetics; Associate Director, Genetics and Solid Tumors Laboratory

Dr. Pritchard is an Assistant Professor of Laboratory Medicine. He is also the associate director of the clinical molecular genetics laboratory in Laboratory Medicine at the University of Washington Medical Center, where he focuses on oncology molecular diagnostics.

Karen Weck, M.D.
Professor, University of North Carolina in Chapel Hill

Karen Weck, MD is Professor of Pathology & Laboratory Medicine and Genetics and Director of the Clinical Molecular Genetics Laboratory at the University of North Carolina in Chapel Hill. She has served as a consultant or advisor to numerous commercial and professional organizations and is a member of the FDA Molecular and Clinical Genetics Devices Panel.

read more

Dr. Weck has been involved in several clinical trials implementing genomic testing for personalized medicine, including somatic mutation testing in cancer to identify response to specific pathway inhibitors, whole exome sequencing to identify mutations in genetic diseases, and pharmacogenomic testing to study the clinical utility of pharmacogenomics guided therapy.

Dr. Weck is co-PI of an NIH NHGRI Clinical Sequencing Exploratory Research award to implement whole exome sequencing for diagnosis of genetic diseases and has had recent grant funding from the NIH office of rare diseases, North Carolina Biotechnology Center, and institutionally-funded initiatives to develop diagnostic genomic testing. Dr. Weck received Bachelor of Science and Doctor of Medicine degrees from Duke University, residency training in Laboratory Medicine at Washington University in St. Louis, and is boarded in Clinical Pathology and Molecular Genetic Pathology.

read less